The story of MTBC Inc (NASDAQ: MTBC) keeps getting better. It is proving its potential to compound capital in the long-term as an advantaged acquirer.
MTBC has made plenty of progress since my previous article. It is executing its M&A playbook well. MTBC acquired Meridian Medical Management (a former GE Healthcare IT company) less than 6 months after its previous major acquisition of Carecloud. The acquisition is likely priced slightly above 1x sales. This is a cheap price compared to the industry average 2-3x, and is cheap likely because of the lack of profitability and sub-par topline growth. MTBC is the rare buyer who can solve both problems. It aggressively offshores without losing service quality to increase profits and retain customers. It is also bundling add-on services (eg telehealth) to its core RCM product to increase topline growth.
Investors are only starting to recognize the value of MTBC’s playbook. The stock moved from $6.50 pre-Meridian in May 2020 to about $11.00 yesterday after a series of sell-side commentaries. MTBC’s market cap has finally exceeded $100m, which is likely to attract more investors than when it was a nano-cap company.
Two weeks after acquiring Meridian, management guided to 30% higher annualized revenues and 600bps EBITDA margin improvement (from 12%). That management announced the margin improvement early in the integration process is a sign of confidence in cost reduction and a repeatable M&A playbook.
A notable feature of recent acquisitions involving Meridian and Carecloud is the addition of new services. Meridian added automation services and Carecloud brought telehealth services. Previous M&A had focused on strengthening MTBC’s core RCM products. The new leg of growth involving new services not only support organic growth, but also complement MTBC’s M&A playbook by broadening its target universe and accelerating inorganic growth. Investors should look forward to more sustainable growth as MTBC expands beyond RCM.
MTBC has already exceeded my target price in the previous article. I’ll provide a new target price after the company updates on its capital structure in the next earnings release.
Roku Inc (NASDAQ: ROKU) is the market-share leader in connected TV (CTV) with a 47% share, impressively beating second-place Amazon (85x Roku’s mkt cap) that has 40% share. Roku grew topline by 3.5x and its share price by 7.5x in the past 4 years, despite going head-to-head against mega-cap media peers (Amazon, AT&T, Comcast etc). It will continue to capture the bulk of advertising budgets moving to CTV from linear TV ($70B industry vs Roku $1B revenue) as the largest CTV platform, enjoying a long growth runway. Its chief competitive advantage is superior technology, built on a programming language designed by its founder and CEO, Anthony Wood. Investors are under-estimating the potential of Roku in extracting excellent economics as the dominant provider of OS for TVs (think Microsoft for PCs, Google for Android mobile), and over-estimating the potential of competition to overtake Roku. Roku’s track record of growth-oriented innovations and potential to eventually “tax” every channel on its platform will serve high returns to investors for the foreseeable future.
Traditional linear TV is ripe for disruption. Its distribution system (cable/satellite) is expensive and outdated. Channel bundling forces consumers to pay for content that they don’t want. The lack of a recommendation engine makes content exploration difficult, which is unimaginable to the Netflix/Hulu user served with content aligned to viewing habits. Advertising on linear TV, dependent on Nielsen data, is no longer as effective as targeted ads in the digital age popularized by Google/Facebook.
Roku has disrupted linear TV and beat streaming peers using the cheapest prices in the market, the greatest variety of content, and the most user-friendly interface. A Roku device cost less than half of an Apple TV or Google Chromecast device. Amazon Fire comes closest to matching the price of a Roku device, but does not match content variety. Unlike Apple/Google/Amazon, Roku does not sell content, and thus can offer content from all platforms. Apple TV does not allow users to rent from Google Play. Amazon Fire does not allow purchases on iTunes. Roku, as the “Switzerland” in TV streaming, can offer the greatest variety of content and attract the most users.
The most important advantage that Roku has is also the least understood. It has the most user-centric interface because it is the only OS (operating system) built for TV. OS only work when it is purpose-built. Think of Windows for PC and iOS for mobile phones. Microsoft dominated personal computers, but failed to migrate Windows to mobile phones (remember Windows phones). Apple dominated mobile phones, but could not attract a loyal following for Apple TV, which uses the same interface as iPhones. Competitors are lagging Roku chiefly because they are attempting to re-purpose OS, not designed for TV, for TV. Roku was designed from scratch for nothing but TV. The 5,000+ apps available on Roku is powered by Brightscript, the in-house programming language created singlehandedly by Roku’s founder and CEO. According to this programmer, Brightscript Components are written exclusively in C, which is an incredibly powerful, fast, efficient and portable programming language. It is also an accessible language for most programmers, underlying the potential of Roku to attract more developers and more creative content.
Roku extracts incredible economics as the dominant OS for TVs. Its high-margin (70% gross margin) and recurring revenue stream comes in the form of advertising revenues (Roku calls this platform revenues). Roku shares advertising revenue produced by AVOD (advertising video-on-demand) channels. AVOD is the fastest-growing format because it offers free content to consumers in exchange for display advertisements. The growth of AVOD (eg Tubi, Crackle) is also supported by excessive competition in the familiar SVOD format (subscription video-on-demand eg Netflix, Disney+, HBO etc). Consumers are likely to be reluctant to add new SVOD services after budgets are exhausted, implying that some SVOD players may embrace a pure AVOD or hybrid AVOD/SVOD format (similar to Hulu), and aid the growth of AVOD and ultimately Roku.
Behind Roku is Anthony Wood, an incredible founder and CEO who has the rare combination of technical prowess and business leadership. Wood reminds me of Tobias Lurie, founder and CEO of Shopify. Both started as technically proficient programmers, and created the programming languages that eventually powered their companies (Wood created Brightscript and Lutke created Liquid). Both picked up management and leadership skills after starting their companies, and retained significant ownership throughout the rapid growth of their companies. Wood had started two companies before Roku and even worked under Reed Hastings at Netflix to develop Roku. Investors should be confident of Wood’s ability to lead Roku. The early partnerships with TV manufacturers and retailers to quickly distribute the Roku OS was an effective strategy that Google is trying to replicate now (but likely can’t reach Roku’s success because of OS mismatch). The recent acquisition of Dataxu and partnership with Kroger to advance CTV advertising data analytics is ground-breaking in tech-retail collaborations, and is another proof of Wood’s innovative and effective leadership.
Valuing Roku, like its high-growth TMT peers, is not straightforward because of its heavy investments and low profitability. Because DCF works with positive cash flows, Roku should be valued as if it had achieved steady-state, characterized by normalized investments and profitability. Hence the quantitative valuation of Roku relies on a key qualitative assumption, that is Roku’s current investments are effective enough for the company to achieve steady state in the future. In this model, I assume that Roku grows topline by 30% CAGR and achieves steady-state in 8 years, and generates 30% EBITDA margin (similar to the Trade Desk, the current de facto CTV platform leader). With a terminal multiple of 17 (r=10%, g=4%), Roku is worth about $180/sh (50% upside from current price).
The price target likely underestimates the potential of Roku because of the company’s track record in innovation. It was the first to license OS to TV manufacturers, the first to initiate a major tech-retail partnership in advertising, the first to feature 100+ live channels for free in an intuitive interface, the first content-neutral platform, and the first platform (but not the first channel) to benefit from the fast-growing AVOD format. Investors should expect more growth-oriented innovations in the future. If Roku continues to strengthen its dominant position, it would become the default OS for smart TVs, and extract “taxes” in the form of advertising revenue-share similar to what Google/Apple does for mobile apps today. Every AVOD channel will have to be on Roku and pay “Roku-taxes” because its platform will be the most widely distributed. This is a capital-efficient model that will serve high returns for many years to come.
MTBC Inc (NASDAQ: MTBC) is a healthcare IT company that provides SaaS-based critical back-office services to physician groups and hospitals. The company has emerged as an advantaged acquirer of providers of backend healthcare technology. It acquired 5 companies from 2006-14, and accelerated the pace of acquisitions to 15 from 2014-20 after going public in 2014. The M&A playbook relies extensively on quality and low-cost labor (2400 full-time headcount primarily based in Pakistan, 8x headcount in US) to reduce operating expenses by 50-60% at acquired companies. The fragmented industry provides a long growth runway, which supports increasing operating leverage and potential in reducing funding costs significantly (11% preferred equity is the sole “debt”) to further M&A. MTBC stands out from peers with high 17% ROIC, substantial insider ownership (49%), and proven senior management (3 out of 4 members has executed the M&A playbook together since founding in 2006). Most notably, the company possesses the potential to compound capital in the long-term as an advantaged acquirer.
The B2B, non-consumer-facing nature of MTBC’s services may be unfamiliar to readers. MTBC improves the medical billing reimbursement process, increases collections, and reduces errors in submission, collectively known as revenue cycle management (RCM) services. Complementing the core RCM are practice management services and EHR. Practice management involves patient scheduling, insurance analysis, and other day-to-day workflow functions. EHR, or electronic health records, conducts patient communications and clinical charting electronically to support the billing and reimbursement processes. The RCM industry is stable and mature, growing at low to mid-single digit annually, which implies that consolidation and cost-cuts are central to profitability. Customer retention is usually high (80-95%), highlighting the importance of M&A for growth.
Its latest acquisition involving Carecloud, a high-profile acclaimed SaaS platform, proves the value of its cost-cutting playbook in an increasingly costly RCM industry. Carecloud, which raised a cumulative $150m as of 2019, was sold to MTBC for only $41m, implying large losses for venture capital investors (but great for MTBC) even when Carecloud earned excellent reviews for its product. VC investors likely approved the loss-making sale because of a cloudy outlook for profits from expensive technology and labor investments. RCM providers face several cost-increasing industry trends. Health insurers have complex reimbursement processes because of new laws and payer requirements. Medicare, Medicaid and commercial insurances are increasingly requiring proof of adherence to best practices and improved patient health outcomes to support full reimbursement. Moreover, the recent shift to new insurance codes has dramatically increased the complexity associated with selecting procedure and diagnosis codes needed to support claim submission and reimbursement. Therefore, automated SaaS billings must be complemented by laborious, time-consuming, and expensive human expertise in keeping up with insurance claims and reimbursements practices. MTBC has cracked the code to reduce costs by training a horde of full-time skilled and low-cost labor, based in Pakistan, to handle analytical tasks that support customer-facing personnel based in the US.
Nothing is better at proving MTBC’s value and the industry’s difficulty to cut costs than athenahealth, a RCM industry leader taken private by Elliott Management for $5.5B. athenahealth had targeted 30% operating margins, but could not achieve greater than 16-17% before the transaction. MTBC reported 11%, which was an admirable result before the benefit of scale (athenahealth was 70x the size of MTBC). Excellent execution is rare in the RCM industry because of the increasing complexity of regulations. Hence investors should give MTBC’s industry-leading execution more credit than they do today.
In valuing MTBC, inorganic growth must be considered. Management guided for an additional $100m revenues from M&A by FY21, expanding current revenues by roughly 3x in 2 years (MTBC reported FY19 results in Feb 2020). Management reiterated guidance made in Feb 2020 during the covid-19 debacle, a testament to its excellent execution and stable industry dynamics.
Assuming that revenues reach $170m in FY21 (roughly $100m higher than FY19 revenue and $70m higher than FY20), MTBC is expected to pay $70m at 1x revenue. Judging from previous transaction, $5m of $70m would be in contingent payouts. The $65m would be financed from a combination of preferred stock, cash flow from ops, and cash on balance sheet. The estimated preferred stock raise is $26m with current $35m cash on balance sheet (leaving $4m to maintain day-to-day operations) and assuming FY20-21 cumulative $4m levered FCF.
Based on management guidance in FY20 and projections of $170m revenue in FY21, standard DCF (r=10%, g=3%) results in $240m NAV. Backing out $4m cash and $129m preferreds (incl the est $26m raise) results in about $115m market cap, representing about 46% upside potential.
The calculation above, though based on reasonable assumptions, understates the return potential of MTBC as a long-term compounder. Advantaged acquirers, such as Pool Corp and Watsco, with a sustainable M&A platform are rare. The streak of M&A can be interrupted by the reduction of targets, lack of cheap capital, and executive turnover among other factors. For MTBC, its M&A streak is unlikely to end before reaching a billion-dollar valuation. MTBC is executing in a mature, fragmented industry with few competing acquirers; not dependent on cheap capital for M&A; and having 49% insider ownership that strongly discourages turnover.
Turning Point Brands (NYSE: TPB) is a manufacturer and marketer of OTP (Other Tobacco Products) and hemp-derived CBD products. Attractive product economics, in the form of non-cyclical demand and strong brand loyalty, support pricing power, consistent margins and cash flows, and high returns on capital (~40% gross margin, ~10% FCF margin, 20% ROIC). TPB stock increased from $10 to $55 between 2016 and 2019 on the back of strong growth in vaping, but cratered to $20 after rising teen addiction and increasing lung injuries from illicit vaping products in Q419. The FDA banned most e-cig flavors on January 1 2020, and required manufacturers to go through an arduous, expensive approval process (ie PMTA) to continue sales of e-cig. FDA approval, though costing $10-20mm, will ultimately benefit TPB and other well-capitalized survivors by shutting numerous small players and legitimizing surviving vaping products. The vaping debacle had taken attention away from the established OTP segments that provide at least $50mm FCF (and may account for the entire current value of the company) and the company’s strong balance sheet ($140mm available liquidity), which provides ample liquidity for PMTA approval process and a free call option in the form of transformative M&A targeted at vaping products (ie NewGen segment). As proof of non-cyclical demand and brand loyalty, on April 2, TPB affirmed Q1 guidance, first made in February 26, implying that impacts from Covid-19 are minimal. Valuing the OTP segments as strong cash-flowing businesses and the NewGen segment at cost (ignoring the potential for transformative M&A), the stock provides 77% upside.
The OTP segments – Smokeless and Smoking – generate stable cash flows ($50mm FCF) that fund the growth engine, which is the NewGen segment housing proprietary brands and distribution of third-party brands related to e-cigarette, CBD, and other vaping products (50% revenue CAGR 2014-19 before disruption. More on this later). The OTP segments contain dominant brands in the categories below:
-Chewing tobacco (part of Smokeless). Brands: Stokers (20% market share, 2nd largest in industry), Beech-Nut, Trophy, Durango, Wind River. Collectively 29% market share. Chewing tobacco is cured tobacco in the form of loose leaf, plug, or twist, delivering nicotine without smoke associated with traditional cigarettes. Industry growth is about low single digits;
-Moist snuff (part of Smokeless). Brand: Stoker (4.5% share, one of fastest-growing brands in the market). Moist snuff, also known as snus, is cut tobacco that can be loose or pouched and placed in the mouth. Industry growth is about low single digits;
-Cigarette paper (part of Smoking). Brand: Zig-Zag (35% share in premium market, largest premium brand). Industry is shrinking in low single digits;
-Cigar wraps (part of Smoking) Brand: Zig-Zag (75% share overall).
Buffett said that one may assess the quality of a business by the ease with which it raise prices without losing customers. By this benchmark, the Smokeless segment is a quality business because it raised prices by 4.3% and increased volumes by 3.4% from 2016-19 on average, while expanding EBITDA margins to 38% from 32%. Moist snuff was the key driver, contributing 54% segment revenue. It is manufactured and packaged in the company’s Tennessee and Kentucky facilities in a proprietary process that results in a superior product. In addition, smokeless products align with increasing smoke-free ordinances and increasing consumer awareness of relatively lower health risks compared to traditional combustible tobacco. The Smoking segment is a lower quality business in which revenue has been stagnant since 2016, but it still delivers admirable ~40% EBITDA margins. Smokeless and Smoking collectively generated ~$50m FCF in 2019.
Standard DCF with conservative assumptions shows that the OTP segments are worth at least the entire company value ($400m mkt cap at time of writing). This implies that the market ascribes zero to negative value to TPB’s growth engine, the NewGen segment, and assumes the segment to be consistently loss-making. This dire assessment is very unlikely to play out because of a strong track record of execution, ample liquidity to survive the PMTA process, and favorable competitive dynamics post-PMTA.
Even before the vaping debacle in 2019, the NewGen segment has generated consistently positive EBITDA and FCF from 2016-18. Management balanced product and marketing investments in vaping with profits, displaying shrewd capital allocation. 2019 was the first year in which NewGen suffered EBITDA losses. When vaping sales were disrupted in Q419, management quickly shrunk exposure to the vaping distribution business. They consolidated 4 warehouses into a single facility, eliminated low-margin platforms, and wrote off unsalable inventories because of the FDA flavor ban. The PMTA process will likely cause a large reduction in vaping brands and declining distribution profits. Management has responded optimally by investing more in proprietary brands than in distribution capabilities moving forward. It is unusual for a small-cap company to display a strong track record of execution. This is likely made possible by executives who have decades of experience seeing major shifts in the tobacco business. Larry Wexler, CEO, spent two decades at Altria and 17 years at TPB. Graham Purdy, COO, spent 7 years at Philip Morris and 16 years at TPB.
A major transition in the vaping business is underway. In August 2019, the CDC reported increasing lung injuries associated with vitamin E acetate in THC-containing e-cigarettes and vaping products. It is essential to differentiate between THC and CBD because marijuana-derived THC is illegal (except in low concentrations and when prescribed in certain US states) while hemp-derived CBD is legal (See Appendix for technical information). TPB only deals with CBD, not THC, in vaping products. Furthermore, legal vaping products do not contain vitamin E acetate. TPB has clarified in a statement that it does not sell e-cigarettes and other vaping products containing THC or vitamin E acetate.
Yet TPB and other legitimate manufacturers are subjected to regulation designed to weed out illicit production. To protect consumers from illicit THC/vit E acetate-containing e-cigs and vape products, the FDA requires all vaping manufacturers to receive marketing authorization for vape products through a Premarket Tobacco Product Application (PMTA) pathway. The PMTA is an exhaustive and expensive scientific study that considers the risks and benefits of the tobacco product for public health. The US subsidiary of London-based British American Tobacco, an $83B company, submitted 150,000 pages for its VUSE vaping product. At an estimated cost of $120k per product, a standard vape manufacturer with 10 flavors available in 5 capacities and 3 levels of nicotine content can expect to spend $18mm (10*5*3*120k). Numerous legitimate, in addition to illicit companies, but under-capitalized companies in the fragmented vaping market will either shut down or curtail production, leaving well-capitalized peers with significantly reduced competition. For a $400mm market-cap company, TPB is well-capitalized with $95mm cash, ~$45mm in undrawn revolving credit, and ~$50mm FCF from its OTP segments, more than the $20mm expected in PMTA expenses. TPB has the management capability and liquidity to be successful in the PMTA process.
(As a side note, the FTC recently sued Altria to undo its $12.8B investment in Juul. Should the lawsuit succeed, the largest e-cig manufacturer with >70% market share will lose the backing of one of the largest tobacco companies, further tilting competitive dynamics in the favor of TPB.)
The strong balance sheet provides ammunition for transformative M&A. TPB might had completed deals in Q419 if not for the vaping disruption. Senior management appeared to be on the prowl for strategic acquisitions:
“We are in deep dialogue in several potentially transformative acquisitions. That does not mean we are certain of the outcome, but we’ll most certainly continue to pursue accretive opportunities that can further propel company growth. We have the access to capital, and we will efficiently deploy those resources to accelerate the company momentum.” -CEO Larry Wexler, Q419 earnings call.
“And Jamie, at the end of the day, like I think you guys all are aware, like vape gate was extremely disruptive. We terminated 60 people, right? And we run a tight ship. And so we have real deals in the pipeline, but they require management to push them through. And if it wasn’t for vape gate, we would’ve had deals done in the fourth quarter. So we — the pipeline is, frankly, stronger. We did move management around where we’ve dedicated some resources solely to getting deals done. And those are moving forward.” -CFO Bobby Lavan, Q419 earnings call.
The topic of transformative M&A deserves attention because studies show that the majority of deals destroy value. TPB appears to have defied the curse so far. It has spent ~$50mm in acquisitions since 2016, of which $26mm was spent to develop the NewGen segment from scratch and the balance in a bolt-on acquisition for chewing tobacco (part of Smokeless segment). The NewGen segment was created with three M&A deals, thus it serves as a useful benchmark in assessing management’s ability to create growth from M&A. Against roughly $166mm ($26mm acquisitions + $115mm debt increase from 2016-19 assuming that new debt is taken solely for NewGen + $25m cumulative interest expenses 2016-19) invested on building NewGen since 2016, TPB generated a cumulative ~$393mm revenue and ~$93mm gross profit. This means that in 3 short years, TPB has recouped about 55% of its investment in NewGen before operating expenses (~18% “return on capital”). Excluding expenses associated with the vaping disruption, the figure would be 70% (~23% “return on capital”). We used gross profit as a measure here because TPB reports low capex relative to revenues (capex ~1% revenues), so “growth capex” is likely to be in operating expenses. Gross profit can then be thought as a proxy to profits before growth investments.
The high “return” metrics showed that NewGen had excellent product economics similar to the OTP segments. Shareholders should feel assured that TPB management would continue to engage in value-additive deals. CFO Bobby Lavan seemed eager and excited yet careful about the deal pipeline (likely to be focused entirely on NewGen):
“But deals, you never want to be forced to do deals. The pipeline is strong. The — frankly, it’s — there are a bunch of companies that I bid for in sort of late summer that have come back and said, is that offer still on the table, which is an interesting dynamic. And so we are sort of evaluating that. I will tell you, there is carnage in the street, blood everywhere when it comes to these cannabis in CBD companies. It is — the opportunity set is massive. We’re just — it’s just a capacity issue … So we’ve got this quarter through. We’ve cleaned up our books, reset the business. We moved Jim Murray straight to deal making, which is awesome, and it’s — we’re going to get stuff done.”-CFO Bobby Lavan, Q419 earnings call.
Because the PMTA process is likely to reduce the number of vaping manufacturers significantly, TPB has made the logical decision to pivot from solely being a distributor to a manufacturer and marketer of proprietary vaping brands. Future deal-making is likely to focus on acquiring growing vaping brands. There is little doubt that vaping would continue to grow in popularity, despite the interruption from lung injuries. Stimulant drugs like nicotine are very difficult to quit because of withdrawal symptoms. That is why nearly 40mm Americans still smoke after a 30-year nationwide campaign against smoking. Smokers are always looking to minimize harm when feeding their nicotine addiction. Vaping reduces harm by delivering much less carcinogens and no secondhand smoke compared to combustible cigarettes. The vaping population grew 7-fold from 2011-18, and is likely to continue growing.
In thinking about the valuation of TPB, it’s best to see the company as having 3 businesses with separate risk and growth profiles. The Smokeless segment is established with ~40% EBITDA margins, above-industry growth, and a clear expansion pathway in moist snuff. The Smoking segment is also established with ~40% EBITDA margins, but has a weak industry backdrop and no clear growth drivers. The NewGen segment arguably has the best growth potential, but also the most uncertain future with M&A integration and developing regulations. Each segment is valued below. Summing the below, TPB provides ~77% upside, which excludes the upside potential of transformative M&A in NewGen.
-Smokeless: r=9%. g=4% (2x global GDP). TV multiple=20.8. NPV=$626mm based on historical 7% revenue growth and 40% EBITDA margins.
-Smoking: r=10%. g=0%. TV multiple=10.0. NPV=$288mm based on historical 0% revenue growth and 40% EBITDA margins.
-NewGen: NPV=$166mm (at cost approximated using cash spent on M&A, debt, and interest expenses). Shareholders should be at least confident that management won’t destroy value.
TPB makes products with great economics but unloved dynamics in the current social context. Chewing tobacco and moist snuff are profitable but dirty. Vaping presents great growth prospects but involves addiction, death, federal agencies, and the revival of Big Tobacco. Investors ought to look past the smoke of temporary dynamics, and stare at the long-lived economics of TPB products.
Cannabidiol (CBD) is a compound found in hemp plants and most commonly used to produce CBD hemp oil products. CBD is non-intoxicating and, when derived from hemp, is legal under U.S. federal law. Tetrahydrocannabinol (THC) is a compound found in marijuana plants and is responsible for the euphoric “high” that people experience when they ingest or smoke marijuana. The legal status of THC products differ from state to state.
Corporacion America Airports SA (NYSE: CAAP) is the largest private operator of airports (by number of airports), having a concentration of concessions in Argentina and Latin America. The airport operator has a resilient, utility-like business model with limited competition and high returns through the cycle. The icing is a capable, long-term-oriented controlling shareholder (>80% stake) who is among the wealthiest people in Argentina with a great track record in building value. Airport businesses are rarely for sale, but this one is because of two temporary demand shocks that can’t happen simultaneously at a better time – macroeconomic weakness in Argentina and travel depression related to Covid-19. CAAP generates $280m unlevered FCF relative to $1.4Bn EV. Even using very conservative estimates (5% declined in FCF over 2 years and zero growth in perpetuity), the stock has 80% upside (Target price: $6.70. Current price: $3.70).
CAAP operates 52 airports in 7 countries through government-granted concessions that lasts at least 10 years. CAAP pays “leases” for airports to governments in exchange for the right to collect fees from airlines, passengers, and businesses for their use of airport facilities. Airlines are charged for every take-off, landing, and parking. Passengers are charged fees, which are typically bundled in the cost of air tickets, for the use of airports. Businesses pay for cargo storage, warehouses services, and leases to operate retail stores in airports. By geography, airports based in Latin American accounted for ~90% revenues, in which 60% was from Argentina. By business line, aeronautical revenues contributed 50%, commercial 35%, and construction services 15% of revenues.
Airport operators are recession-resistant businesses that maintain high returns even during economic slowdowns. Argentina has been mired in recession since 2018 (GDP declined by 9% in 2018), yet growth in operating statistics remain strong. Passengers, cargo volume, and aircraft movement showed growth in 2018 (6/5/3% growth respectively). However, it is easy to miss the strong resiliency because revenues showed 15% decline in 2018. The real decline is actually only 0.8%, which supports the resilient picture shown by operating statistics.
Out of the $176m decline in revenue in 2018, $112m was related to the application of IAS 29, an accounting principle required for hyperinflationary economies like Argentina. IAS 29 applies most to companies that receives revenues in Argentinean pesos but reports in other currencies (CAAP reports in USD). Hyperinflation depresses the value of pesos, hence revenues must adjust for the depreciation. However, CAAP receives ~80% revenues in US dollars, so its adjustment for peso depreciation should be much lower than what IAS 29 requires. This means that the nature of the $112m decline was accounting-related, not economic related. Another portion of the decline concerned a $55m decline in construction service revenue, which was really capital expenditures rather than revenue (more on this later). Excluding the two declines, the real decline was $9m (<1% decline), not $176m (15% decline).
The resilient fundamentals were accompanied by ~14-16% returns-on-capital, which were maintained even during recessionary periods. Returns are defined as after-tax adjusted EBITDA minus capex, and capital as the sum of debt and equity. CAAP applies IFRIC 12 like many infrastructure companies, which makes the calculation of ROC more complex. The key point to note in IFRIC 12 is that all investments required by the concession agreement are recognized as revenue, and the actual cost of these investments are recognized as cost. Companies typically do not recognize investments as revenues because investments do no immediately result in revenue. Yet those who apply IFRIC 12 are typically toll-like businesses that can quickly gain revenues from investments. For example, a busy airport may invest in a parking structure that can realize revenue quickly upon completion.
To adjust EBITDA, I treat “construction services cost” as capex (on top of what CAAP already reports as capex) because this is the actual cost of investments, and discount “construction services revenue” to a present value. Going back to the previous example, the airport building the parking structure should only recognize additional revenue from parking fees after the structure is completed, but not before. We can discount future revenues to present by using a factor of 0.5, which roughly corresponds to revenues coming 9 years later and an 8% discount rate (discount factor=1/(1.08)^9=0.5), both of which are conservative estimates considering the low-risk nature of the project. Based on the table below, 2018 adjusted EBITDA should be ~$350m (=445.9-196.3+0.5*198.4) before tax/working capital/reported capex, and not the stated $445.9m. These adjustments, plus tax and working capital changes, result in ROC ranging 14-16% between 2016-18. To achieve 16% ROC in 2018 when the key country reported 9.5% decline in GDP in the same year is formidable, demonstrating a recession-resistant business model.
Change in working capital (receivables and inventory only)
ROC (unlevered FCF/total capital)
ROE (levered FCF/total capital)
(As a side note, ROE was even higher than ROC because of declining tax expenses caused by over-payment. The focus here is on ROC because of significant debt and interest expenses.)
The growth runway in airport fundamentals generally correlate to macroeconomic growth, so it is necessary for CAAP investors to consider the economic growth of Argentina (60% 2018 revenues). As mentioned, Argentina is mired in recession and hyper-inflationary territory. Its debt has been declared unsustainable by the IMF, which lent a record $44Bn to the country. However, the current administration is the first ever in Argentina making credible moves to restore economic growth. It has demonstrated an ambitious start by setting a two-month timeline to restructure $67Bn debt by March 2020 to keep interest expenses manageable for economic growth, and already announced the hiring of advisors in the first week of March. The timeline keeps the administration accountable, and is far more preferable to the mysterious, hostile tactics during the 15-year odyssey of Argentina’s previous default in 2001. For the first time in its history, the country also agreed to Article IV talks that would allow the IMF to inspect Argentina’s accounts before a new agreement is signed, surprising the market because it has almost always been hostile to IMF scrutiny. Article IV talks would assure bondholders as they head into restructuring talks that Argentina is under IMF supervision.
Perhaps the most promising is the appointment of Martin Guzman as finance minister . Guzman has an impressive resume. He is the protégé of Joseph Stiglitz, a Nobel laureate and influential economist. He is a leading expert on sovereign debt policies, and has testified before the US Congress on Puerto Rico’s debt crisis and at the United Nations about the need for a better international system for resolving sovereign debt crises. Most important, he demonstrated a sound understanding of the importance of coordinated policy action and sustained growth, instead of mere monetary tightening, to combat inflation in this op-ed. There is no doubt that Guzman is the best chance for Argentina to get back on sound economic footing.
CAAP is cheap on an absolute basis (I’m not a fan of relative valuation). Assuming no growth and a 10% discount rate, a 3-year DCF results in $2.8Bn EV (~2x current market value). The same DCF produces 140% upside from current price when growth is assumed at 2% (roughly the growth of global GDP, which is a low estimate). Current valuation implies that CAAP shrinks FCF by 9% annually in perpetuity, which is very unlikely given the mission-critical nature of airports, low risks of disruption and substitution, and strong tailwinds in air travel. To allow for the temporary disruption of Covid-19 and recession in Argentina, I assume a 5% decline in FCF per year for the next two years and zero growth in perpetuity, resulting in an ~80% upside from current price.
The target price does not account for upside related to actions from management, which has proven competent for the past 20 years since the founding of CAAP. Management is aligned with shareholders because the founding and managing family owns 82.1% of CAAP while public shareholders own the balance. CEO Martin Eurnekian is the nephew of founder Eduardo Eurnekian, who had a great track record in building value (net worth: $1.5Bn) from diverse business interests in media, energy, infrastructure, and finance as a shrewd entrepreneur. Management transition had been stable without typical family strife with only one CEO transition in the history of the firm. Eduardo had led the company since its founding in 1998, and passed the CEO position to Martin after the IPO. Martin, now 40, had started his first job at CAAP when he was 18, and spent the past 22 years “doing everything one could imagine” at CAAP.
In 2020, it is irresponsible to discuss a travel-related business without thinking about disruptions from Covid-19. The virus, about 5-10x more contagious than seasonal influenza, has almost reached the proportions of a global pandemic. Experts estimate the mortality rate to be ~1% or lower (the current rate announced by the WHO is 3.4%. This is too high because it is based on backward-looking data). I cannot offer more insights concerning the virus. What I can do is offer some extent of clarity based on current facts:
-Covid-19 is infectious but not deadly to most people. This means that most of us (about 90%) can resist the virus. This also means that Covid-19 does not constitute an end-of-the-world-as-we-know-it event.
-A vaccine is possible. Estimated time to production varies from one to two years. What is important to know is that the human race has her best minds working on this day and night. Betting against the human race (ie shorting the market thinking that the virus would destroy the global economy) is unwise.
-Every government and central bank is ready to unleash significant monetary and fiscal stimulus to combat the impact of the virus. Betting against the Fed, ECB, and their peers is foolish.
-The world seems to be over-reacting with mass quarantines, but over-reaction is better than under-reaction. China under-reacted at first by suppressing information about the virus, then the country over-reacted by placing 50 million citizens in mandatory quarantine. It worked – the growth of new cases stalled. Italy under-reacted at first too, then over-reacted by enforcing quarantines and travel restrictions on the entire country. The US over-reacted in a different way by having the Fed cut rates and the White House floating stimulus measures. Over-reaction is good because it preemptively reduces the impact, biological or otherwise, of the virus. But over-reaction can also be misunderstood as a signal that the virus is an end-of-the-world-as-we-know-it event. Over-reaction stops the virus from becoming worse, but does not indicate a worsening of its impacts.
It is easy to be pessimistic by reading headlines showing the relentless growth of new cases. However, reality is often a lagging indicator of our efforts. You exercise to lose weight, but your body typically does not show weight loss until later. Humankind is racing to contain the virus, which will eventually be conquered. The only question is when. I am optimistic knowing what will happen but not knowing when.
CAAP generates high returns through the cycle, owns valuable airport concessions, and demonstrates incentivized management with a good track record in building value. When the sky clears of temporary demand shocks in the form of macroeconomic weakness in Argentina and reduced travel from Covid-19, the stock will be ready for takeoff.